心通醫療-B(02160.HK):超額配售權獲悉數行使 涉及3084.3萬股額外股份
格隆匯 2 月 7日丨心通醫療-B(02160.HK)公佈,聯席全球協調人(為其本身及代表國際包銷商)已於2021年2月5日(於交易時段後)悉數行使招股章程所述的超額配售權,涉及合共3084.3萬股額外股份,佔行使任何超額配售權前全球發售項下初步可供認購發售股份總數的15%。
公司將按全球發售項下每股股份的發售價每股股份12.2港元(不包括1.0%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費)配發及發行超額配售股份。超額配售股份將用於促使向Shanghai MicroPort歸還3084.3萬股股份,該等股份此前用於補足國際發售中股份的超額分配。
經扣除有關悉數行使超額配售權的包銷佣金以及公司應付的其他估計開支後,公司將自配發及發行超額配售股份收取額外所得款項淨額約3.61億港元。
上市委員會已批准超額配售股份上市及買賣。有關超額配售股份預期將於2021年2月10日(香港時間)上午九時正在聯交所主板上市及開始買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.